Can ProQR Therapeutics N.V’s (PRQR) drop of -17.75% in a week be considered a lucky break?

On Monday, ProQR Therapeutics N.V (NASDAQ: PRQR) was -6.20% drop from the session before settling in for the closing price of $2.42. A 52-week range for PRQR has been $1.61 – $4.62.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 55.62%. When this article was written, the company’s average yearly earnings per share was at 5.85%. With a float of $74.28 million, this company’s outstanding shares have now reached $81.68 million.

In terms of profitability, gross margin is 92.11%, operating margin of -166.82%, and the pretax margin is -134.62%.

ProQR Therapeutics N.V (PRQR) Insider and Institutional Ownership

Also, it is sometimes useful to examine the sentiment of large-scale investors toward ProQR Therapeutics N.V stocks. The insider ownership of ProQR Therapeutics N.V is 28.03%, while institutional ownership is 17.68%.

ProQR Therapeutics N.V (PRQR) Latest Financial update

Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 5.85% per share during the next fiscal year.

ProQR Therapeutics N.V (NASDAQ: PRQR) Trading Performance Indicators

You can see what ProQR Therapeutics N.V (PRQR) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.33. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 12.09.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.32, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.43 in one year’s time.

Technical Analysis of ProQR Therapeutics N.V (PRQR)

The latest stats from [ProQR Therapeutics N.V, PRQR] show that its last 5-days average volume of 0.36 million was superior to 0.31 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 21.59%. Additionally, its Average True Range was 0.24.

During the past 100 days, ProQR Therapeutics N.V’s (PRQR) raw stochastic average was set at 20.88%, which indicates a significant increase from 13.85% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 56.67% in the past 14 days, which was lower than the 145.76% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $3.26, while its 200-day Moving Average is $2.34. Now, the first resistance to watch is $2.43. This is followed by the second major resistance level at $2.58. The third major resistance level sits at $2.71. If the price goes on to break the first support level at $2.15, it is likely to go to the next support level at $2.02. The third support level lies at $1.87 if the price breaches the second support level.

ProQR Therapeutics N.V (NASDAQ: PRQR) Key Stats

There are 81,680K outstanding shares of the company, which has a market capitalization of 234.27 million. As of now, sales total 7,050 K while income totals -30,430 K. Its latest quarter income was 4,230 K while its last quarter net income were -8,920 K.